Get started
Author

Hila Magen

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
2015 · Sagar Lonial, Meletios Dimopoulos, et al. · New England Journal of Medicine · 1,324
PDF
Systemic amyloidosis from A (AA) to T (ATTR): a review
2020 · E. Muchtar, A. Dispenzieri, et al. · Journal of Internal Medicine · 331
Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma
2018 · Guy Ledergor, Assaf Weiner, et al. · Nature Medicine · 262
Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial
2020 · Maria-Victoria Mateos, Hareth Nahi, et al. · The Lancet Haematology · 256
Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX
2018 · Meletios A. Dimopoulos, Jesus San-Miguel, et al. · Haematologica · 213
PDF
How I treat cryoglobulinemia
2016 · Eli Muchtar, Hila Magen, et al. · Blood · 185
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study
2020 · Meletios A. Dimopoulos, Sagar Lonial, et al. · Blood Cancer Journal · 155
PDF
Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT ‐2 follow‐up and post‐hoc analyses on progression‐free survival and tumour growth
2017 · Meletios A. Dimopoulos, Sagar Lonial, et al. · British Journal of Haematology · 135
PDF
Phase I study of the heparanase inhibitor roneparstat: an innovative approach for ultiple myeloma therapy
2018 · Monica Galli, Manik Chatterjee, et al. · Haematologica · 117
PDF
Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma
2025 · Yael C. Cohen, Hila Magen, et al. · New England Journal of Medicine · 110
PDF
First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
2023 · Yael C Cohen, Daniel Morillo, et al. · Journal of Clinical Oncology · 87
Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study
2018 · Mohamad Mohty, Mohamad Mohty, et al. · Clinical Lymphoma Myeloma & Leukemia · 82
BNT162b2 mRNA COVID-19 vaccination in immunocompromised patients: A prospective cohort study
2021 · Galia Rahav, Yaniv Lustig, et al. · EClinicalMedicine · 75
PDF
Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab in High-Risk Smoldering Multiple Myeloma
2019 · Timothy A. Brighton, Amit Khot, et al. · Clinical Cancer Research · 71
Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment
2016 · Hila Magen, Eli Muchtar · Therapeutic Advances in Hematology · 67
PDF
A practical review on carfilzomib in multiple myeloma
2016 · Eli Muchtar, Morie A. Gertz, et al. · European Journal Of Haematology · 65
PDF
Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open‐label Phase II study
2020 · Ajai Chari, Paula Rodriguez‐Otero, et al. · British Journal of Haematology · 64
PDF
Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma
2022 · Saad Z. Usmani, Hareth Nahi, et al. · Haematologica · 61
PDF
Blocking of Transient Receptor Potential Vanilloid 1 (TRPV1) promotes terminal mitophagy in multiple myeloma, disturbing calcium homeostasis and targeting ubiquitin pathway and bortezomib-induced unfolded protein response
2020 · Katia Beider, Evgenia Rosenberg, et al. · Journal of Hematology & Oncology · 52
PDF
Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab
2025 · Shaji Kumar, María-Victoria Mateos, et al. · New England Journal of Medicine · 48
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial
2022 · Meletios A Dimopoulos, Paul G Richardson, et al. · The Lancet Haematology · 47
The impact of individual comorbidities on non-relapse mortality following allogeneic hematopoietic stem cell transplantation
2018 · Joshua A. Fein, Avichai Shimoni, et al. · Leukemia · 47
Real‐world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective study
2022 · Tamir Shragai, Hila Magen, et al. · British Journal of Haematology · 46
PDF
CXCL13 chemokine is a novel player in multiple myeloma osteolytic microenvironment, M2 macrophage polarization, and tumor progression
2022 · Katia Beider, Valeria Voevoda-Dimenshtein, et al. · Journal of Hematology & Oncology · 45
PDF
Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study
2015 · Eli Muchtar, Moshe E. Gatt, et al. · British Journal of Haematology · 39
PDF
Works count: 172
Citation count: 4,701
H-index: 28
I10-index: 52
Year
Topic
Type